Interferon-Alpha-2a Plus Nucleosides for HIV Infection: Increased Toxicity, Transient Viral Load Decreases CDC Daily UpdateImportant note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to CDC Daily Update main menu





DonateNow




Interferon-Alpha-2a Plus Nucleosides for HIV Infection: Increased Toxicity, Transient Viral Load Decreases

Reuters Health Information Services (12/15/97)

Abstract: The addition of interferon-alpha-2a to the drug combination of zidovudine and zalcitabine appears to be harmful over time, according to a study published in the December 1 issue of the Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. Researchers for AIDS Clinical Trials Group Study 197 report that larger doses of interferon produced substantially higher hematologic toxicity and peripheral neuropathy. The researchers did not notice a significant difference in CD4 cell counts in any of the patients. They suggest, however, that intermediate doses of interferon or a different dosing schedule might produce more lasting effects.


971216
AD972300

Copyright © 1997 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.

.